Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Current Assets (2016 - 2026)

United Therapeutics' Current Assets history spans 17 years, with the latest figure at $3.7 billion for Q4 2025.

  • On a quarterly basis, Current Assets fell 4.42% to $3.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.7 billion, a 4.42% decrease, with the full-year FY2025 number at $3.7 billion, down 4.42% from a year prior.
  • Current Assets hit $3.7 billion in Q4 2025 for United Therapeutics, up from $3.5 billion in the prior quarter.
  • Over the last five years, Current Assets for UTHR hit a ceiling of $4.0 billion in Q3 2024 and a floor of $2.0 billion in Q1 2021.
  • Historically, Current Assets has averaged $3.2 billion across 5 years, with a median of $3.3 billion in 2022.
  • Biggest five-year swings in Current Assets: soared 45.48% in 2022 and later fell 12.66% in 2025.
  • Tracing UTHR's Current Assets over 5 years: stood at $2.3 billion in 2021, then soared by 45.48% to $3.4 billion in 2022, then grew by 5.05% to $3.6 billion in 2023, then increased by 9.09% to $3.9 billion in 2024, then fell by 4.42% to $3.7 billion in 2025.
  • Business Quant data shows Current Assets for UTHR at $3.7 billion in Q4 2025, $3.5 billion in Q3 2025, and $3.8 billion in Q2 2025.